New weapon unleashed: immune cells reprogrammed to hunt down tough blood cancers

NCT ID NCT06542250

Recruiting now Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

Summary

This study is testing a new drug called AZD5492 for adults whose B-cell cancers have come back or stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug helps control the cancer. The drug works by directing the patient's own immune T-cells to attack the cancer cells.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Research Site
RECRUITING

La Jolla, California, 92093, United States
Research Site
WITHDRAWN

Boston, Massachusetts, 02215, United States
Research Site
RECRUITING

Hackensack, New Jersey, 07601, United States
Research Site
RECRUITING

New York, New York, 10021, United States
Research Site
RECRUITING

New York, New York, 10029, United States
Research Site
RECRUITING

Charlotte, North Carolina, 28203, United States
Research Site
RECRUITING

Winston-Salem, North Carolina, 27157, United States
Research Site
RECRUITING

Houston, Texas, 77030, United States
Research Site
RECRUITING

Seattle, Washington, 98109, United States
Research Site
RECRUITING

Melbourne, 3000, Australia
Research Site
RECRUITING

Nedlands, 6009, Australia
Research Site
RECRUITING

Calgary, Alberta, T2N 5G2, Canada
Research Site
RECRUITING

Toronto, Ontario, M5G 2M9, Canada
Research Site
RECRUITING

Montreal, Quebec, H3T 1R2, Canada
Research Site
RECRUITING

Hangzhou, 310003, China
Research Site
RECRUITING

Shanghai, 200025, China
Research Site
RECRUITING

København Ø, 2100, Denmark
Research Site
RECRUITING

Pessac, 33604, France
Research Site
RECRUITING

Villejuif, 94805, France
Research Site
RECRUITING

München, 81675, Germany
Research Site
RECRUITING

Ulm, 89081, Germany
Research Site
RECRUITING

Würzburg, 97080, Germany
Research Site
RECRUITING

Bologna, 40138, Italy
Research Site
RECRUITING

Milan, 20133, Italy
Research Site
RECRUITING

Chūōku, 104-0045, Japan
Research Site
RECRUITING

Kashiwa, 277-8577, Japan
Research Site
RECRUITING

Barcelona, 08035, Spain
Research Site
RECRUITING

L'Hospitalet de Llobregat, 08908, Spain
Research Site
RECRUITING

Madrid, 28040, Spain

Conditions

Explore the condition pages connected to this study.

B-CELL MALIGNANCIES